Mazdutide (5mg)

Mazdutide (IBI362) is a once-weekly injectable dual agonist targeting both GLP-1 (glucagon-like peptide-1) and glucagon (GCGR) receptors, developed by Innovent Biologics. This dual-receptor mechanism distinguishes it from pure GLP-1 agonists by adding glucagon receptor activation, which increases energy expenditure and enhances hepatic fat mobilization beyond appetite suppression alone.

The GLP-1 component reduces appetite, slows gastric emptying, and improves insulin sensitivity — mechanisms shared with semaglutide. The GCGR component provides a distinct metabolic advantage by increasing basal metabolic rate, promoting hepatic gluconeogenesis suppression, and mobilizing visceral fat through cAMP-mediated lipolysis. This dual action creates synergistic weight loss and metabolic benefits that address both energy intake (GLP-1) and energy expenditure (GCGR).

Phase 2 and Phase 3 clinical trials in China have demonstrated significant weight loss (up to ~19% at higher doses over 24 weeks) and improvements in cardiometabolic parameters. Mazdutide is being investigated for obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD/MASH). It is not yet approved for therapeutic use outside China and is provided strictly for research purposes.